StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock analysis

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.33−0.03 (-9.30%)

Close on Nov 12, 2026Market cap $61.87MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth1Performance2Health5Dividend0

Weak8 of 30 checks passed

Heron Therapeutics passes 8 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
1/6
Past performance
2/6
Financial health
5/6
Dividend
0/6

What stands out

  • No debt

    Heron Therapeutics has no borrowings on its latest balance sheet.

  • Revenue growing 10%+ a year

    Revenue grew 12.9% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Elevated bankruptcy risk

    The Altman Z-score is -10.57; above 3 is the safe zone and below 1.8 the distress zone.

  • P/B above the industry

    Heron Therapeutics's price-to-book of 13.88 is above the Drugs median of 2.29.

  • Growing slower than the industry

    Revenue grew -4.4% over the last twelve months; the Drugs median is 8.0%.

  • Gross margin slipping

    Gross margin was 71.5% over the last twelve months, against 73.9% a year earlier.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Heron Therapeutics's price-to-book of 13.88 is above the Drugs median of 2.29.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing 10%+ a year

    Revenue grew 12.9% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -4.4% over the last twelve months; the Drugs median is 8.0%.

  • Guidance issued

    The latest outlook (2026 Full-Year Net Revenue, May 11, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin slipping

    Gross margin was 71.5% over the last twelve months, against 73.9% a year earlier.

Past performance2/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity below the industry

    Heron Therapeutics's return on equity of -218% is below the Drugs median of -58.9%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -14.5% over the last twelve months, against a 5-year average of -107%.

  • Net margin above the industry

    Heron Therapeutics's net margin of -14.5% is above the Drugs median of -53.0%.

Financial health5/6

  • No debt

    Heron Therapeutics has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 2.33 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -10.57; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Heron Therapeutics has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Heron Therapeutics. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Drugs median 2.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$2.54M
Value traded per 1% price move
$161.05K

Downside

High risk

Typical loss in a bad month
59.6%
Volatility (annualized)
96%
Sharpe ratio, 1 year
-0.75
Beta to the S&P 500 (5Y)
1.81

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

73.3%+14.1 pts over 5 years

Operating margin

-1.6%+255.8 pts over 5 years

Net margin

-13.0%+243.4 pts over 5 years

See a number that looks wrong?